A receptor-antibody hybrid hampering MET-driven metastatic spread

Chiara Modica(Candiolo Cancer Institute), Elisa Vigna(Candiolo Cancer Institute)

Journal of Experimental & Clinical Cancer Research

January 14, 2021

10.1186/s13046-020-01822-5

Cited by 11

Related Papers

Monovalency Unleashes the Full Therapeutic Potential of the DN-30 Anti-Met Antibody

|Journal of Biological Chemistry|2010|77

Dual Constant Domain‐Fab: A novel strategy to improve half‐life and potency of a Met therapeutic antibody

|Molecular Oncology|2016|14

Molecular Engineering Strategies Tailoring the Apoptotic Response to a MET Therapeutic Antibody

|Cancers|2020|3

Genetic Ablation of the MET Oncogene Defines a Crucial Role of the HGF/MET Axis in Cell-Autonomous Functions Driving Tumor Dissemination

|Cancers|2023|1